Abstract
Invasive fungal disease (IFD) is a major threat to the success of haematopoietic stem cell transplantation (HSCT), especially in the modern era of reduced-intensity conditioning regimens and wide range of donor sources. Changing fungal epidemiology and mortality rates of 8090% for certain pathogens1 are adding to the challenge for haematologists and oncologists. Against this background, speakers at the symposium ‘Antifungal treatment in the bone marrow transplant (BMT) setting: Perspectives from clinical experience’, held during the 36th Annual Meeting of the European Group for Blood and Marrow Transplantation in Vienna, Austria on 2124 March 2010, presented data showing the impact of recent epidemiological and clinical IFD studies on everyday practice in Europe and the US.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
